There are two major types of pancreatic cancer, endocrine pancreas cancer and exocrine pancreas cancer. The patient with pancreatic cancer are more susceptible to jaundice, weight loss, diabetes, or pain in the stomach area or back. The mortality is increasing with the increasing prevalence of this type of cancer many countries. Thus, it requires regular surveillance.
The Global Pancreatic Cancer Market is expected to grow at a CAGR of 8.1 % during the forecast period 2017-2023.
Increasing prevalence of pancreatic cancer, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology are expected to fuel the market during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.
Some of key the players in the market are Pharmacyte Biotech Inc. (U.S.), OncoGenex Pharmaceuticals Inc. (U.S.), Oncolytics Biotech (Canada), Diffusion Pharmaceuticals (U.S.), Polaris Pharmaceuticals, Inc. (U.S.), Sun BioPharma, Inc. (U.S.), Midatech Pharma PLC (U.K.), Eli Lilly and Company (U.S.), Celgene Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Amgen, Inc. (U.S.), Novartis International AG (U.S.), Clovis Oncology (U.S.), and others.
The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.
On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.
Access Sample Copy @ https://www.marketresearchfuture.com/sample_request/1638 .
On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.
The Americas dominate the global pancreatic cancer market owing to the presence of huge patient population with cancer, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global pancreatic cancer market as result of increasing focus of various government agencies on the treatment of diseases such as pancreatic cancer. Moreover, the growing public awareness about pancreatic cancer is likely to boost the European market.
Asia Pacific is the fastest growing market across the globe. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development are projected to drive the market in China and India.
Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/1638 .
The Middle East and Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –